LAB insider trading
HealthcareSTANDARD BIOTOOLS INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About STANDARD BIOTOOLS INC.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
Company website: www.standardbio.com
LAB insider activity at a glance
FilingIQ has scored 232 insider transactions for LAB since Apr 4, 2022. The most recent filing in our index is dated Apr 6, 2026.
Across the full history, 75 open-market purchases
and 9 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LAB insider trades is 48.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for LAB?
- FilingIQ tracks 232 Form 4 insider transactions for LAB (STANDARD BIOTOOLS INC.), covering filings from Apr 4, 2022 onwards. 18 of those were filed in the last 90 days.
- Are LAB insiders net buyers or net sellers?
- Across the full Form 4 history for LAB, 75 transactions (32%) were open-market purchases and 9 (4%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LAB insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is LAB in?
- STANDARD BIOTOOLS INC. (LAB) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $430.71M.
Methodology & sources
Every LAB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.